



OPEN ACCESS

ORIGINAL ARTICLE

# Modest rise in chlamydia and gonorrhoea testing did not increase case detection in a clinical HIV cohort in Ontario, Canada

Ann N Burchell,<sup>1,2</sup> Ramandip Grewal,<sup>1</sup> Vanessa G Allen,<sup>3,4</sup> Sandra L Gardner,<sup>1,2</sup> Veronika Moravan,<sup>1</sup> Ahmed M Bayoumi,<sup>5,6,10</sup> Rupert Kaul,<sup>5</sup> Frank McGee,<sup>7</sup> Margaret (Peggy) E Millson,<sup>2</sup> Robert S Remis,<sup>2</sup> Janet Raboud,<sup>2,8</sup> Tony Mazzulli,<sup>3,4,9</sup> Sean B Rourke,<sup>1,10,11</sup> on behalf of the OHTN Cohort Study Team

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/sextrans-2014-051647>).

For numbered affiliations see end of article.

## Correspondence to

Dr Ann N Burchell, Ontario HIV Treatment Network, Suite 600, 1300 Yonge Street, Toronto, ON, Canada M4T 1X3; [aburchell@ohntn.on.ca](mailto:aburchell@ohntn.on.ca)

Received 17 April 2014

Revised 24 July 2014

Accepted 29 July 2014

## ABSTRACT

**Objectives** We described patterns of testing for chlamydia and gonorrhoea infection among persons in specialty HIV care in Ontario, Canada, from 2008 to 2011.

**Methods** We analysed data from 3165 participants in the OHTN Cohort Study attending one of seven specialty HIV care clinics. We obtained chlamydia and gonorrhoea test results via record linkage with the provincial public health laboratory. We estimated the proportion of participants who underwent testing annually, the positivity rate among those tested and the proportion diagnosed with chlamydia or gonorrhoea among all under observation. We explored risk factors for testing and diagnosis using multiple logistic regression analysis.

**Results** The proportion tested annually rose from 15.2% (95% CI 13.6% to 16.7%) in 2008 to 27.0% (95% CI 25.3% to 28.6%) in 2011 ( $p < 0.0001$ ). Virtually all were urine-based nucleic acid amplification tests. Testing was more common among men who have sex with men (MSM), younger adults, Toronto residents, persons attending primary care clinics and persons who had tested in the previous year or who had more clinic visits in the current year. We observed a decrease in test positivity rates over time. However, the annual proportion diagnosed remained stable and in 2011 this was 0.97% (95% CI 0.61% to 1.3%) and 0.79% (95% CI 0.46% to 1.1%) for chlamydia and gonorrhoea, respectively. Virtually all cases were among MSM.

**Conclusions** Chlamydia and gonorrhoea testing increased over time while test positivity rates declined and the overall proportion diagnosed remained stable, suggesting that the modest increase in testing did not improve case detection.

(STIs) have been found among persons living with HIV in similar developed nations such as the USA, Australia and parts of Europe.<sup>3,4</sup> The burden of STI coinfection is especially high among HIV-positive men who have sex with men (MSM).<sup>5,6</sup>

Chlamydia and gonorrhoea infection among persons with HIV is particularly concerning because STIs can enhance HIV infectiousness and sequelae may be more pronounced.<sup>7-9</sup> Regular screening is important in this population. Canadian and US guidelines recommend testing for chlamydia and gonorrhoea at least annually among sexually active gay, bisexual and other MSM, regardless of HIV status.<sup>7,10</sup> For people with HIV, US guidelines recommend annual routine screening for curable STIs and British guidelines recommend offering an annual full sexual health screen.<sup>10,11</sup>

Few published studies have examined patterns of chlamydia and gonorrhoea testing in HIV clinic populations, yet such information is crucial to inform public health strategies and clinical guidelines for people living with HIV. Our first objective was to expand knowledge on testing patterns in this population by estimating rates and correlates of testing among persons in HIV care in Ontario from 2008 to 2011. Since Canada has universal health-care, any differences seen would reflect non-financial barriers. Our second objective was to determine the burden of and risk factors for a new diagnosis of chlamydia or gonorrhoea, measured as annual positivity rates among those tested and the overall proportion diagnosed among all in care. Given the reported increases in chlamydia and gonorrhoea cases in Ontario since 2002,<sup>2</sup> we hypothesised a priori that testing and new diagnosis rates would increase over the study period.

## METHODS

Our setting was the province of Ontario, which has the largest proportion (44%) of new HIV diagnoses in Canada.<sup>12</sup> Our data source was the ongoing Ontario HIV Treatment Network Cohort Study (OCS); its study design has been described previously.<sup>13</sup> Briefly, the OCS source population consists of voluntary, consented participants aged 16 and older diagnosed with HIV infection receiving medical care at 10 specialty HIV clinics.

## INTRODUCTION

Since the early 2000s, chlamydia and gonorrhoea incidence has risen in many urban centres, including in Ontario, Canada.<sup>1</sup> Case reporting for chlamydia and gonorrhoea increased 79 and 23%, respectively, from 2002 to 2011, with average annual increases of 10 and 2% per year, respectively, since 2008. Although the majority of chlamydia cases are among young women, gonorrhoea cases are more commonly reported among men (57%), and of these, 42% report sex with other men.<sup>2</sup> High rates of sexually transmitted infections



► <http://dx.doi.org/10.1136/sextrans-2014-051700>

**To cite:** Burchell AN, Grewal R, Allen VG, *et al.* *Sex Transm Infect* Published Online First: [please include Day Month Year] doi:10.1136/sextrans-2014-051647

Participants were interviewed annually using structured questionnaires and clinical data were abstracted from clinic records.<sup>13</sup> The study protocol, research instruments and forms received ethical approval from the University of Toronto Human Subjects Review Committee and from the study sites.

### Chlamydia and gonorrhoea testing

We obtained testing data for HIV viral load and bacteriological tests for chlamydia and gonorrhoea through record linkage with the provincial Public Health Ontario Laboratories (PHOL), the sole provider of HIV viral load tests in Ontario and the primary provider for chlamydia and gonorrhoea tests submitted by STI clinics. In other clinical settings such as HIV clinics or primary care clinics, chlamydia and gonorrhoea tests may either be submitted to the PHOL or to private laboratories. The PHOL began keeping computerised records of chlamydia and gonorrhoea tests in 2008 and testing was available by culture or nucleic acid amplification testing (NAAT). Prior to 2009, NAAT was performed using the Becton Dickinson ProbeTec assay (BD Biosciences, Sparks, Maryland, USA). Starting in July 2009, the PHOL used the Gen-Probe Aptima assay (Gen-Probe, San Diego, California, USA). NAAT testing is only performed for urine, endocervical or urethral specimens, whereas culture is offered for genital and non-genital sites (eg, rectal, pharyngeal, conjunctival swabs). Culture is the only diagnostic method that allows for antibiotic resistance testing of *Neisseria gonorrhoeae*.

Each clinic participating in the OCS received a questionnaire to establish to which laboratories they submitted orders for chlamydia and gonorrhoea testing. Seven of 10 clinics responded that they submit all specimens to the PHOL; two were primary care clinics and the remainder were hospital-based clinics.

### Analysis

There were 5933 OCS enrollees as of December 2011. We restricted the analysis to persons under observation at any time from 2008 to 2011 (1738 removed) and to participants who attended one of the seven clinics that submitted chlamydia and gonorrhoea tests to the PHOL (1030 removed). The latter exclusion ensured that all chlamydia and gonorrhoea testing ordered by the participating HIV clinic and any STI clinic in Ontario would be observable. The final sample size for analysis was 3165 participants. We conducted all statistical analyses using SAS V.9.3 (SAS Institute, Inc., Cary, North Carolina, USA). All p values were two-sided, and statistical significance was determined using the conventional p value of <0.05.

We used descriptive statistics to characterise participants included in the analysis and compared them with participants attending the three clinics excluded from the analysis. Next, we examined the proportion of participants that underwent testing at least once at any time from 2008 to 2011 and at least once in each calendar year when they were under follow-up ('annual testing').

We defined a case as a participant with  $\geq 1$  positive test result in a given calendar year. We calculated annual positivity rates among those tested. We calculated the proportion diagnosed with chlamydia or gonorrhoea among all participants under observation in each calendar year whether or not they underwent testing in that year. This is an underestimate of true prevalence since the numerator excludes undetected (likely asymptomatic) cases among untested patients.

We used multiple logistic regression and a generalised estimating equations framework with an autoregressive correlation structure to explore potential correlates of testing and risk factors for diagnosis of chlamydia and gonorrhoea. Each

person-year was modelled as a unique observation and all ORs and proportions are reported with 95% CIs. Persons with unknown or missing information for a covariate were excluded from models given the small numbers with missing data. To determine whether a previous gonorrhoea or chlamydia test increased the odds of subsequent testing, we excluded the year 2008 and participants with  $\leq 2$  years of prospective follow-up (n=341) from our testing analysis. For the diagnosis outcome, we conducted a sensitivity analysis to explore whether there were any differences when restricting to testers. For both the testing and diagnosis outcomes, we first built a multivariable model containing all considered covariates, then excluded those

**Table 1** Characteristics of OHTN Cohort Study participants included in the analysis of chlamydia and gonorrhoea testing, 2008–2011

|   | All participants<br>(n=3165) | MSM<br>(n=2179)     |
|---|------------------------------|---------------------|
| Mean age at baseline (SD)*                                | 45.5 (10.0)                  | 46.7 (9.9)          |
| Sex   |                              |                     |
| Male: MSM   | 68.9%                        | –                   |
| Male: non-MSM   | 12.1%                        | –                   |
| Female  | 16.9%                        | –                   |
| Unknown†  | 2.2%                         | –                   |
| Median year of HIV diagnosis (IQR)                        | 1998<br>(1992–2004)          | 1996<br>(1991–2003) |
| Region of Ontario   |                              |                     |
| Toronto   | 83.5%                        | 86.5%               |
| Other   | 16.5%                        | 13.5%               |
| Ethnicity   |                              |                     |
| White   | 61.7%                        | 74.1%               |
| Black/African   | 14.3%                        | 4.2%                |
| Aboriginal  | 4.5%                         | 4.4%                |
| Other   | 16.6%                        | 17.1%               |
| Unknown   | 3.0%                         | 0.2%                |
| Education   |                              |                     |
| High school or less                                       | 28.6%                        | 23.02%              |
| Trade school or college                                   | 29.1%                        | 30.1%               |
| University  | 35.3%                        | 42.9%               |
| Unknown   | 7.0%                         | 3.9%                |
| Income  |                              |                     |
| Less than \$20 000  | 39.2%                        | 34.7%               |
| \$20 000–\$59 999   | 34.3%                        | 37.7%               |
| \$60 000 or more  | 17.0%                        | 21.7%               |
| Unknown   | 9.3%                         | 5.8%                |
| Median # months of prospective follow-up (IQR)            | 36.0 (26.4–42.0)             | 36 (27.6–43.2)      |
| Median CD4 cell count/mm <sup>3</sup> at baseline (IQR)*‡ | 470 (330–640)                | 480 (340–650)       |
| Antiretroviral medication any time during follow-up       | 92.8%                        | 93.4%               |
| Viral load at baseline*                                   |                              |                     |
| Undetectable (<50 copies/mL)                              | 56.8%                        | 58.8%               |
| Detectable but suppressed (50–199 copies/mL)              | 7.9%                         | 8.0%                |
| Unsuppressed (200+ copies/mL)                             | 34.1%                        | 32.2%               |
| Unknown   | 1.2%                         | 1.0%                |

\*Baseline was defined as the later of 1 January 2008 or the date of enrolment.

†Reasons for missing data among persons with unknown sex and MSM status:

0.16% missing data on sex; 2.04% males with missing data on history of sex with men.

‡CD4 cell count was missing for 2.4% of participants.

MSM, men who have sex with men.

**Table 2** Annual chlamydia and gonorrhoea testing among participants attending selected clinics of the OHTN Cohort Study, 2008–2011

|   | 2008                | 2009                | 2010                | 2011                |
|---|---------------------|---------------------|---------------------|---------------------|
| Per cent tested for chlamydia/gonorrhoea* |                     |                     |                     |                     |
| All†                                      | 15.2 (13.7 to 16.7) | 20.5 (19.0 to 22.1) | 24.1 (22.5 to 25.7) | 27.0 (25.3 to 28.6) |
| MSM†                                      | 18.6 (16.6 to 20.6) | 23.9 (22.0 to 25.8) | 28.9 (26.9 to 30.9) | 32.4 (30.3 to 34.4) |
| Non-MSM male†                             | 3.7 (1.5 to 6.0)    | 5.6 (3.0 to 8.2)    | 6.9 (4.1 to 9.7)    | 10.1 (6.8 to 13.4)  |
| Women†                                    | 10.3 (7.1 to 13.4)  | 17.5 (13.8 to 21.1) | 17.5 (14.0 to 20.9) | 18.5 (15.0 to 22.0) |
| Chlamydia positivity rate‡                |                     |                     |                     |                     |
| All                                       | 5.5 (4.6 to 8.1)    | 4.7 (3.9 to 6.4)    | 4.8 (4.0 to 6.4)    | 3.6 (2.9 to 5.0)    |
| MSM                                       | 6.1 (4.9 to 9.0)    | 5.4 (4.4 to 7.4)    | 5.4 (4.4 to 7.2)    | 3.7 (2.8 to 5.2)    |
| Non-MSM male                              | 0.0 (0.0 to 36.9)   | 0.0 (0.0 to 21.7)   | 0.0 (0.0 to 16.8)   | 3.1 (0.1 to 17.4)   |
| Women                                     | 2.8 (0.1 to 15.5)   | 1.4 (0.0 to 7.6)    | 2.5 (0.3 to 9.0)    | 3.5 (0.7 to 10.1)   |
| Proportion diagnosed with chlamydia§      |                     |                     |                     |                     |
| All                                       | 0.8 (0.5 to 1.8)    | 1.0 (0.6 to 1.8)    | 1.2 (0.8 to 2.0)    | 1.0 (0.6 to 1.7)    |
| MSM                                       | 1.1 (0.6 to 2.4)    | 1.3 (0.8 to 2.3)    | 1.5 (1.0 to 2.6)    | 1.2 (0.7 to 2.1)    |
| Non-MSM male                              | 0.0 (0.0 to 1.4)    | 0.0 (0.0 to 1.2)    | 0.0 (0.0 to 1.2)    | 0.3 (0.0 to 1.8)    |
| Women                                     | 0.3 (0.0 to 1.3)    | 0.2 (0.0 to 1.3)    | 0.4 (0.1 to 1.6)    | 0.6 (0.1 to 1.9)    |
| Gonorrhoea positivity rate‡               |                     |                     |                     |                     |
| All                                       | 5.4 (2.9 to 7.8)    | 2.9 (1.5 to 4.3)    | 2.7 (1.5 to 4.0)    | 3.0 (1.8 to 4.2)    |
| MSM                                       | 5.5 (2.8 to 8.2)    | 3.5 (1.8 to 5.2)    | 3.2 (1.8 to 4.7)    | 3.6 (2.1 to 5.1)    |
| Non-MSM male                              | 10.0 (0.3 to 55.7)  | 0.0 (0.0 to 21.7)   | 0.0 (0.0 to 17.6)   | 0.0 (0.0 to 11.5)   |
| Women                                     | 3.0 (0.1 to 16.9)   | 0.0 (0.0 to 5.1)    | 0.0 (0.0 to 4.8)    | 0.0 (0.0 to 4.3)    |
| Proportion diagnosed with gonorrhoea§     |                     |                     |                     |                     |
| All                                       | 0.7 (0.4 to 1.1)    | 0.6 (0.3 to 0.9)    | 0.6 (0.4 to 0.9)    | 0.8 (0.5 to 1.1)    |
| MSM                                       | 1.0 (0.5 to 1.5)    | 0.8 (0.4 to 1.2)    | 0.9 (0.5 to 1.3)    | 1.1 (0.7 to 1.6)    |
| Non-MSM male                              | 0.4 (0.0 to 1.7)    | 0.0 (0.0 to 1.2)    | 0.0 (0.0 to 1.2)    | 0.0 (0.0 to 1.2)    |
| Women                                     | 0.3 (0.0 to 1.3)    | 0.0 (0.0 to 0.9)    | 0.0 (0.0 to 0.8)    | 0.0 (0.0 to 0.8)    |

Results shown as percentages with 95% CIs in parentheses.

\*Virtually all (99%) tests were simultaneously co-tested for both pathogens.

†Statistically significant increase from 2008–2011 ( $p < 0.05$ ).

‡The positivity rate is the per cent with a reactive test among all tested in that year.

§The proportion diagnosed is the per cent with a reactive test among all patients in care and under observation in that year.

MSM, men who have sex with men.

that were neither associated with the outcome nor considered confounders for the remaining covariates.

## RESULTS

At the start of follow-up in 2008–2011, participants attending the included clinics were aged 45 years, on average (table 1). The majority were men (81.0%), many of whom self-identified as gay or bisexual or reported sex with other men as an HIV risk factor (85.1%). The 3165 participants were followed a median of 3.0 years for a sum total of 8442 person-years. When compared with the 1030 participants attending clinics excluded from the analysis, included participants were similar in terms of year of HIV diagnosis and CD4 cell count at baseline (see online supplementary table). However, all excluded participants attended clinics outside Toronto, were slightly younger, fewer were MSM and higher proportions reported Aboriginal ethnicity and lower educational achievement and income.

### Chlamydia and gonorrhoea testing

We linked 3476 chlamydia and 3449 gonorrhoea tests to participants. Virtually all tests (99%) consisted of simultaneous co-testing for both pathogens. Among all persons tested ( $n = 1041$ ), the majority of tests (87.0%, 3034/3486) were urine-based NAAT. Only 3.9, 4.1 and 4.9% were cultured using specimens from the genital, rectal or pharyngeal tract, respectively.

In all, 38.8% (95% CI 37.1% to 40.5%) of patients were tested at least once in 2008–2011. There was a significant increase in testing from 2008 to 2011 ( $p < 0.0001$ ) (table 2).

Most tests (86.6%) were ordered by participating HIV clinics; other tests were ordered by sexual health/STI/community health clinics (2.8%) or by other health providers (10.6%) such as non-HIV specialist family physicians. Among those tested, the median number of tests per person per year was 1.0 (IQR 1.0–2.0). Testers underwent testing a median of 2.0 times (75%ile 4.0 times). Among those tested at least twice, the median intertest interval was 4.1 months (IQR 2.6–7.8) for persons whose tests were non-reactive and 2.0 months (IQR 0.93–3.7) for persons who had at least one reactive test.

Correlates of testing included younger age, attending a primary care clinic, Toronto residence, having undergone testing in the previous year and being a MSM (table 3). We used the frequency of viral load testing as a proxy for clinic attendance and found that participants who had at least two viral load tests per year had higher odds of having also been tested for chlamydia/gonorrhoea. We observed no associations between testing and socioeconomic status variables (ie, race, education, gross personal income; data not shown). After adjusting for covariates, testing rates were no different among women compared with MSM.

We further examined testing patterns in the subset of participants who were under observation soon after HIV diagnosis and care entry in 2008–2011. Annual testing rates were higher in the year of HIV diagnosis/care entry (38.0%, 35/92) compared with later years (21.9%, 2271/8093;  $p < 0.0001$ ). Adjustment for recent HIV diagnosis/care entry did not alter the trend of increased testing over calendar time (data not shown).

**Table 3** Correlates of annual testing for chlamydia/gonorrhoea among participants attending selected clinics of the OHTN Cohort Study

|  | Person years of observation* | Per cent tested | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|--|------------------------------|-----------------|------------------------|----------------------|
| Each additional calendar year                    |                              |                 | 1.20 (1.14 to 1.25)    | 1.27 (1.17 to 1.39)  |
| Sex  |                              |                 |                        |                      |
| Male: MSM  | 5722                         | 28.5            | Referent               | Referent             |
| Male: non-MSM                                    | 898                          | 7.1             | 0.19 (0.14 to 0.27)    | 0.47 (0.35 to 0.64)  |
| Female   | 1289                         | 17.6            | 0.54 (0.44 to 0.67)    | 0.91 (0.73 to 1.14)  |
| Age (years)                                      |                              |                 |                        |                      |
| <30  | 320                          | 40.0            | Referent               |                      |
| 30–39  | 1209                         | 33.3            | 0.76 (0.56 to 1.03)    |                      |
| 40–49  | 3309                         | 25.4            | 0.54 (0.40 to 0.72)    |                      |
| 50+  | 3218                         | 17.3            | 0.36 (0.26 to 0.48)    |                      |
| Each additional decade                           |                              |                 | 0.68 (0.63 to 0.73)    | 0.72 (0.67 to 0.77)  |
| Region   |                              |                 |                        |                      |
| Other  | 1208                         | 3.9             | Referent               | Referent             |
| Toronto  | 6848                         | 27.5            | 9.38 (6.71 to 13.1)    | 2.27 (1.61 to 3.19)  |
| Viral load tests in calendar year                |                              |                 |                        |                      |
| 1 test   | 705                          | 15.6            | Referent               | Referent             |
| 2–3 tests  | 4015                         | 21.9            | 1.39 (1.16 to 1.68)    | 1.65 (1.25 to 2.15)  |
| 4 or more tests                                  | 3172                         | 29.3            | 1.83 (1.51 to 2.21)    | 2.72 (2.07 to 3.59)  |
| Clinic type                                      |                              |                 |                        |                      |
| Tertiary   | 4748                         | 9.7             | Referent               | Referent             |
| Primary  | 3308                         | 44.4            | 7.35 (6.31 to 8.56)    | 3.81 (3.24 to 4.48)  |
| Tested for chlamydia/gonorrhoea in previous year |                              |                 |                        |                      |
| No   | 5799                         | 13.4            | Referent               | Referent             |
| Yes: non-reactive                                | 1392                         | 59.9            | 26.4 (22.6 to 30.9)    | 7.03 (5.92 to 8.34)  |
| Yes: reactive                                    | 106                          | 75.5            | 47.6 (25.3 to 89.4)    | 15.6 (9.04 to 27.0)  |

Multiple logistic regression with generalised estimating equations. Each person year was modelled as a unique observation (n=8056 person-years among 2854 participants). We excluded the year 2008 and any participant with less than two years of prospective follow-up to allow for estimation of the effect of having tested in the previous calendar year. See text for details.

\*The sum total of years that participants were under observation.

MSM, men who have sex with men.

### Diagnosis with chlamydia or gonorrhoea

There were 86 diagnosed cases of chlamydia and 64 cases of gonorrhoea. Among persons tested, the positivity rates decreased from 2008 to 2011 (table 2). Nevertheless, the overall annual proportion diagnosed remained stable. Virtually all cases were among MSM (80/86 chlamydia cases and 62/64 gonorrhoea cases). Not quite half (27/64) of gonorrhoea cases were cultured; none had decreased susceptibility to the first-line oral therapy cefixime (as defined at that time by PHOL as a minimum inhibitory concentration  $\geq 0.25$   $\mu\text{g/mL}$ ) or to ceftriaxone. Test positivity was high among the few patients who were cultured using extragenital specimens. For oral specimens, 18% (32) and 8.2% (14) were positive for chlamydia or gonorrhoea, respectively. For rectal specimens, 16.0% (23) were chlamydia positive and 19% (28) gonorrhoea positive.

### Risk factors for diagnosis with chlamydia or gonorrhoea among gay and other MSM

Risk factor analysis was possible for MSM (table 4). Young age was a risk factor for chlamydia and gonorrhoea; age was not statistically significant for gonorrhoea when restricting to testers (0.79, 95% CI 0.61 to 1.02). A diagnosis of gonorrhoea was more likely among men who had unsuppressed viral load in the same calendar year. Finally, in unadjusted models, attendance at a primary care clinic was associated with a diagnosis of chlamydia, but was no longer statistically significant in the multivariable model (table 4) or when restricting to testers (data not shown).

### DISCUSSION

Annual chlamydia and gonorrhoea testing increased among persons in HIV care in Ontario, Canada, from 15.2% in 2008 to 27.0% in 2011. Despite the rise, testing rates observed in this study were less than expected according to Canadian and international guidelines.<sup>7 10 11</sup> Our findings confirm a notable burden of chlamydia and gonorrhoea infection among HIV-positive MSM in our setting. In 2011, the proportion of MSM diagnosed with chlamydia or gonorrhoea was 1.2% (95% CI 0.71% to 1.7%) and 1.1% (95% CI 0.67% to 1.6%), respectively. Among other men and women, chlamydia was less commonly diagnosed (2011, men: 0.32%, 95% CI 0.01% to 1.8%; 2011, women: 0.64%, 95% CI 0.13% to 1.9%) and we observed no cases of gonorrhoea among non-MSM males and women in 2011.

Strengths of our analysis included the use of a large sample of patients from multiple clinics that ordered tests from a single laboratory. Nevertheless, our findings may have excluded some undiagnosed cases because the majority of patients were untested and there was virtually no testing of non-urethral sites. In a US military HIV cohort, diagnoses of chlamydia and gonorrhoea increased after the introduction of routine semiannual urine-based screening although the positivity rates among those tested remained constant.<sup>14</sup> Testing of non-urethral sites merits consideration as it has been shown to be cost-saving due to improved case detection.<sup>15</sup> Among asymptomatic MSM in an urban STI clinic in San Francisco, urethral-only screening missed 84% of infections, whereas screening of the anal and pharyngeal sites missed only 9.8% of cases.<sup>16</sup> Canadian and US



**Table 4** Risk factors for diagnosis with chlamydia and gonorrhoea co-infection among HIV-positive MSM among participants attending selected clinics of the OHTN Cohort Study, 2008–2011

|  | Person years of observation* | Chlamydia           |                        |                       | Gonorrhoea          |                        |                       |
|--|------------------------------|---------------------|------------------------|-----------------------|---------------------|------------------------|-----------------------|
|  |                              | Per cent diagnosed† | Unadjusted OR (95% CI) | Adjusted OR (95% CI)‡ | Per cent diagnosed† | Unadjusted OR (95% CI) | Adjusted OR (95% CI)‡ |
| Each additional calendar year            |                              |                     | 1.02 (0.85 to 1.21)    | 1.03 (0.85 to 1.24)   |                     | 1.05 (0.84 to 1.31)    | 1.09 (0.85 to 1.40)   |
| Initiated antiretroviral treatment       |                              |                     |                        |                       |                     |                        |                       |
| No                                       | 562                          | 2.49                | Referent               | Referent              | 2.67                | Referent               | Referent              |
| Yes                                      | 6799                         | 1.19                | 0.48 (0.26 to 0.90)    | 1.01 (0.50 to 2.07)   | 0.82                | 0.31 (0.16 to 0.59)    | 0.80 (0.38 to 1.69)   |
| Age (years)                              |                              |                     |                        |                       |                     |                        |                       |
| <30                                      | 279                          | 6.09                | Referent               |                       | 3.23                | Referent               |                       |
| 30–39                                    | 888                          | 3.04                | 0.45 (0.24 to 0.84)    |                       | 1.58                | 0.52 (0.14 to 1.89)    |                       |
| 40–49                                    | 3034                         | 1.02                | 0.17 (0.09 to 0.32)    |                       | 1.15                | 0.59 (0.19 to 1.84)    |                       |
| 50+                                      | 3160                         | 0.63                | 0.12 (0.06 to 0.23)    |                       | 0.41                | 0.20 (0.06 to 0.72)    |                       |
| Each additional decade                   |                              |                     | 0.47 (0.37 to 0.60)    | 0.49 (0.38 to 0.64)   |                     | 0.57 (0.45 to 0.73)    | 0.64 (0.50 to 0.81)   |
| Max viral load in calendar year          |                              |                     |                        |                       |                     |                        |                       |
| Undetectable/suppressed (<200 copies/mL) | 5605                         | 1.09                | Referent               | Referent              | 0.68                | Referent               | Referent              |
| Unsuppressed (200 copies/mL or greater)  | 1638                         | 2.01                | 1.76 (1.13 to 2.74)    | 1.18 (0.69 to 2.03)   | 2.01                | 2.95 (1.81 to 4.83)    | 2.12 (1.13 to 3.93)   |
| Clinic type                              |                              |                     |                        |                       |                     |                        |                       |
| Tertiary                                 | 3767                         | 0.74                | Referent               | Referent              | 0.64                | Referent               | Referent              |
| Primary                                  | 3594                         | 1.86                | 2.47 (1.51 to 4.05)    | 1.59 (0.84 to 3.00)   | 1.31                | 2.10 (1.21 to 3.65)    | 2.09 (0.90 to 4.85)   |

Multiple logistic regression with generalised estimating equations. Each person year was modelled as a unique observation (n=7361 person-years among 2179 men).

\*The sum total of years that participants were under observation.

†The per cent per year with a reactive test among all patients in care and under observation.

‡Adjusted for all variables shown plus clinic.

MSM, men who have sex with men.

guidelines recommend oral and rectal testing for persons engaging in oral and rectal intercourse<sup>7 10</sup>; however, such tests were rarely done in our setting, limiting their epidemiological interpretation due to likely diagnostic workup bias. Furthermore, some patients likely underwent testing with other healthcare providers who submitted tests to private laboratories unavailable to us. Therefore, we interpret our observed rates of testing and diagnosis as underestimates.

Additional limitations may include selection biases due to volunteer participation and clinic inclusion criteria. OCS participants are generally representative of cumulative HIV diagnoses in Ontario in terms of sex, geographic region, age at diagnosis and HIV exposure category<sup>17</sup>; however, they under-represent the recently diagnosed. Among the clinics included in this analysis, approximately 50% of all clinic patients were active participants in the OCS; compared with non-participants, participants tend to be older, diagnosed in the more distant past, MSM and generally healthier as measured by CD4 cell count and viral load.<sup>18</sup> Participants included in the analysis were similar to those attending excluded clinics for year of HIV diagnosis and CD4 cell count at baseline, but were younger, with higher socioeconomic status, and MSM. Altogether, we propose that our findings would be most generalisable for MSM and women in continuous HIV care, but may not be representative of younger, more recently diagnosed persons, especially those not in HIV care.

We compared our findings with rates of notifiable disease reporting in Ontario in 2011. For men, rates of chlamydia and gonorrhoea case reporting were 0.19 and 0.04%, respectively, and for women these were 0.35 and 0.03%, respectively.<sup>1</sup> Therefore, our observed diagnosis rates among HIV-positive MSM were sixfold higher for chlamydia and 27-fold higher for gonorrhoea than those reported for the general male population

in Ontario. Conversely, diagnosis rates among other men and women living with HIV were consistent with rates for the general population.

Among MSM in our cohort, chlamydia and gonorrhoea diagnoses were more likely among younger men, as we have also observed for syphilis.<sup>6</sup> Gonorrhoea was more common among men with unsuppressed viral load in the same calendar year; it is difficult to establish causality for this association as it may be that gonorrhoea infection led to an increase in viral load.<sup>10 19</sup> Nevertheless, HIV infectiousness may have been greater among men with gonorrhoea. Chlamydia was more common among men attending primary care clinics, but we attribute this finding to higher rates of testing. We did not observe differences in proportions diagnosed according to antiretroviral treatment status, similar to HIV cohorts in Madrid and Baltimore.<sup>20 21</sup>

Chlamydia and gonorrhoea testing was more common among patients attending a primary care clinic, which may be due to a greater emphasis on sexual health and STI screening in the primary care setting.<sup>7</sup> Moreover, in 2008 one of the participating primary care clinics instituted a reminder system regarding annual check-ins for STI screening. Higher proportions of testing were seen among MSM and those with more viral load tests in that year, suggesting more opportunities for testing among patients with more HIV care visits. Testing was also more common among younger participants and those tested in the preceding year, similar to the HIV clinic cohort in Baltimore.<sup>22</sup> We also observed similar correlates of testing for syphilis in our cohort, although annual rates of testing for syphilis were considerably higher at 55% per year in 2010.<sup>6</sup> Altogether, this suggests that efforts to improve HIV care engagement may have secondary benefits for sexual health promotion.

Observed diagnosis rates were generally consistent with studies of clinical HIV populations elsewhere based on data

from testing ordered as part of clinical care.<sup>5 22</sup> In the Baltimore cohort, the proportion diagnosed with chlamydia or gonorrhoea between 1999 and 2007 ranged from 0.4 and 1.5%.<sup>22</sup> In an MSM population in two HIV outpatient clinics in the Netherlands, the prevalence of urethral chlamydia and gonorrhoea was 0.3 and 1.4%, respectively.<sup>5</sup> Consistent with our findings of very few cases among women, Remis and colleagues observed zero prevalence of chlamydia and gonorrhoea among 126 HIV-positive women of African-Caribbean ethnicity in Toronto in 2009–2010.<sup>23</sup>

Chlamydia and gonorrhoea testing increased over time while test positivity declined and the overall proportion diagnosed remained stable, suggesting that the modest increase in testing did not improve case detection, contrary to hypothesis. This is comparable to findings in Baltimore where diagnoses remained stable among HIV patients despite a similarly slight increase in testing from 12% in 1999 to 33% in 2007.<sup>22</sup> We propose two competing hypotheses to explain these findings. Either earlier testing patterns were adequate to detect most new cases of chlamydia/gonorrhoea or the modest gains in testing were insufficient to detect a pool of likely asymptomatic infection. One would need to conduct a prevalence study among all patients to determine whether expanded screening is warranted. If the latter proved true, our experience in this setting is that clinical guidelines alone are insufficient to maximise screening uptake,<sup>6 24</sup> as others have observed elsewhere,<sup>21 25</sup> suggesting that systemic changes to healthcare practice would need to be explored.

Our findings of a notable burden of chlamydia and gonorrhoea among HIV-positive MSM have implications for prevention and care. We need to better understand the optimal strategies to promote chlamydia and gonorrhoea testing among MSM living with HIV and ensure that asymptomatic infection does not go undiagnosed. It is concerning that so few were cultured or tested at extragenital sites. Public health agencies in Canada and around the world are pressing for increased vigilance for antibiotic-resistant gonorrhoea strains, which have increased in prevalence.<sup>26 27</sup> This is critical for persons with HIV who may already be challenged by immune suppression. Clinical failures following treatment with cefixime have now been documented in our setting.<sup>28</sup> We support the national recommendation for culture of all symptomatic MSM patients prior to gonorrhoea treatment to monitor antibiotic resistance.<sup>26</sup> We also recommend more frequent collection and testing of pharyngeal and rectal samples—important reservoirs of chlamydia and gonorrhoea infection.<sup>27</sup>

### Key messages

- ▶ There is a notable burden of chlamydia and gonorrhoea infection among HIV-positive men who have sex with men in care.
- ▶ Increased testing did not increase the proportion diagnosed with chlamydia or gonorrhoea; however, testing is still below Canadian and international guidelines.
- ▶ Consideration should be given to making systematic changes to healthcare practice and increasing extragenital screening to maximise screening uptake.
- ▶ Culturing specimens when testing for gonorrhoea will help monitor the increasing burden of antibiotic resistant gonorrhoea.

### Author affiliations

- <sup>1</sup>Ontario HIV Treatment Network, Toronto, Ontario, Canada
- <sup>2</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
- <sup>3</sup>Public Health Laboratories, Public Health Ontario, Toronto, Ontario, Canada
- <sup>4</sup>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
- <sup>5</sup>Department of Medicine, University of Toronto, Toronto, Ontario, Canada
- <sup>6</sup>Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
- <sup>7</sup>AIDS Bureau, Ontario Ministry of Health and Long Term Care, Toronto, Ontario, Canada
- <sup>8</sup>Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
- <sup>9</sup>Mount Sinai Hospital/University Health Network, Toronto, Ontario, Canada
- <sup>10</sup>Centre for Research on Inner City Health, The Keenan Research Centre in the Li KaShing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada
- <sup>11</sup>Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

**Handling editor** Jackie A Cassell

**Acknowledgements** We thank OHTN staff for administrative support (Samantha Robinson, Robert Hudder, Kevin Challacombe, Mark Fisher, Brooke Ellis) and extend our appreciation to the participating clinics, interviewers and chart abstractors who provide support for data collection. We also acknowledge the Public Health Ontario Laboratories for supporting record linkage with the HIV viral load and chlamydia and gonorrhoea test databases. We gratefully acknowledge all of the people living with HIV who volunteer to participate in the OHTN Cohort Study and the work of the OCS Governance Committee: Darien Taylor, Dr Evan Collins, Dr Greg Robinson, Shari Margolese, Patrick Cupido, Tony Di Pede, Rick Kennedy, Michael Hamilton, Ken King, Brian Finch, Lori Stoltz, Adrian Betts, Colleen Price, Tracey Conway, John MacTavish, Claire Kendall, Anita Benoit, Rosie Thein, Brian Huskins, Les Bowman, Dr Ahmed Bayoumi, Dr Clemon George, and Dr Curtis Cooper.

**Collaborators** The OHTN Cohort Study Team consists of Dr Sean B Rourke (Principal Investigator, University of Toronto and OHTN), Dr Ann Burchell (Co-Principal Investigator, OHTN), Dr Sandra Gardner (OHTN), Dr Sergio Rueda (OHTN), Dr Ahmed Bayoumi, Dr Kevin Gough and Dr Darrell Tan, St. Michael's Hospital; Dr Jeffrey Cohen, Windsor Regional Hospital; Dr Curtis Cooper, Ottawa General Hospital; Dr Don Kilby, University of Ottawa Health Services; Dr Mona Loutfy and Dr Fred Crouzat, Maple Leaf Medical Clinic; Dr Anita Rachlis and Dr Nicole Mittmann, Sunnybrook Health Sciences Centre; Dr Janet Raboud and Dr Irving Salit, Toronto General Hospital; Dr Edward Ralph, St. Joseph's Health Care; Dr Roger Sandre, Sudbury Regional Hospital; Dr Marek Smieja, Hamilton Health Sciences, McMaster University Medical Centre; and Dr Wendy Wobeser, Hotel Dieu Hospital.

**Contributors** ANB was the principal investigator who conceived the project, obtained funding, and directed the analysis and manuscript writing; she is the guarantor. RG conducted the analysis and drafted the manuscript. ANB and SBR directed data collection at clinic sites. VGA and TM directed laboratory analysis at the PHOL and its interpretation. SLG, VM and JR provided statistical expertise. AMB, RK, FM, MEM and RSR contributed to the study protocol and guided interpretation. All authors provided critical input into the analysis, read an earlier version of the paper, provided substantive feedback and approved the final paper.

**Funding** This work was supported by Canadian Institutes of Health Research (CIHR) (operating grant 111146 to ANB); a CIHR New Investigator award to ANB; a CIHR-Ontario Ministry of Health and Long-term Care Chair in Applied Health Services Research to AMB; and an OHTN Career Scientist award to JR. The OHTN Cohort Study is funded by the AIDS Bureau, Ontario Ministry of Health and Long-Term Care.

**Disclaimer** The opinions, results and conclusions are those of the authors and no endorsement by the Ontario HIV Treatment Network or Public Health Ontario is intended or should be inferred.

**Competing interests** None.

**Ethics approval** University of Toronto.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The OHTN may authorise the collection, use and disclosure of OCS Data for the purpose of scholarly research if the proposal for the research project has been reviewed and approved and the research project principal investigator and all other members of the research project team have signed a researcher's agreement with the OHTN and adhere to all relevant OCS data and research policies.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

- 1 Public Health Agency of Canada. *Reported cases and rates STI 2010*. Ottawa: Public Health Agency of Canada, 2012. <http://www.catie.ca/sites/default/files/Reported-cases-and-rates-STI-2010.pdf>
- 2 Ontario Agency for Health Protection and Promotion (Public Health Ontario). *Reportable Disease Trends in Ontario, 2011*. Toronto, ON: Queen's Printer for Ontario, 2014.
- 3 Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. *Sex Transm Infect* 2011;87:183–90.
- 4 Van de Laar TJW, Matthews GV, Prins M, *et al*. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *AIDS Lond Engl* 2010;24:1799–812.
- 5 Heiligenberg M, Rijnders B, Schim van der Loeff MF, *et al*. High prevalence of sexually transmitted infections in HIV-infected men during routine outpatient visits in the Netherlands. *Sex Transm Dis* 2012;39:8–15.
- 6 Burchell AN, Allen VG, Moravan V, *et al*. Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000–2009. *BMC Infect Dis* 2013;13:246.
- 7 Public Health Agency of Canada. *Canadian guidelines on sexually transmitted infections*. Ottawa: Public Health, 2010. <http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php>
- 8 Thyagarajan S, Reddy E, Venkatesan C, *et al*. Genital chlamydial infection in STD patients: Its relation to HIV infection. *Indian J Med Microbiol* 2005; 23:37.
- 9 Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex Transm Dis* 1992;19:61–77.
- 10 Centers for Disease Control and Prevention. *Sexually transmitted diseases treatment guidelines*, 2010. Atlanta, GA, Report No.: Volume 59, No. RR-12, 2010.
- 11 Fakoya A, Lamba H, Mackie R, *et al*. *2007 UK guidelines for the management of sexual and reproductive health (SRH) of people living with HIV infection*. UK: BHIVA, BASHH, FFPRHC, 2007. <http://www.bashh.org/documents/91/91.pdf>
- 12 Government of Canada PHA of C. At a Glance—HIV and AIDS in Canada: Surveillance Report to December 31st, 2012—Public Health Agency of Canada. 2013 [cited 11 December 2013]. <http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2012/dec/index-eng.php>
- 13 Rourke SB, Gardner S, Burchell AN, *et al*. Cohort profile: the Ontario HIV Treatment Network Cohort Study (OCS). *Int J Epidemiol* 2013;42:402–11.
- 14 Spaulding AB, Lifson AR, Iverson ER, *et al*. Gonorrhoea or chlamydia in a US military HIV-positive cohort. *Sex Transm Infect* 2012;88:266–71.
- 15 Chesson HW, Bernstein KT, Gift TL, *et al*. The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection. *Sex Transm Dis* 2013;40:366–71.
- 16 Marcus JL, Bernstein KT, Kohn RP, *et al*. Infections missed by urethral-only screening for chlamydia or gonorrhoea detection among men who have sex with men. *Sex Transm Dis* 2011;38:922–4.
- 17 Remis R, Liu J. *HIV/AIDS in Ontario: Preliminary Report, 2011*. 2013. [http://www.ohemu.utoronto.ca/doc/PHERO2011\\_report\\_preliminary.pdf](http://www.ohemu.utoronto.ca/doc/PHERO2011_report_preliminary.pdf)
- 18 Raboud J, Su D, Burchell AN, *et al*. Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. *BMC Med Res Methodol* 2013;13:31.
- 19 Ward H, Ronn M. The contribution of STIs to the sexual transmission of HIV. *Curr Opin HIV AIDS* 2010;5:305–10.
- 20 Jiménez E, Pedrazuela MG, Pérez MM, *et al*. Prevalence of pharyngeal infection by *Neisseria gonorrhoeae* among human immunodeficiency virus-positive men who have sex with men in downtown Madrid, 2011. *Int J STD AIDS* 2013;24:875–8.
- 21 Berry SA, Ghanem KG, Page KR, *et al*. Gonorrhoea and chlamydia testing rates of HIV-infected men: low despite guidelines. *Sex Transm Infect* 2010;86:481–4.
- 22 Berry SA, Ghanem KG, Page KR, *et al*. Increased gonorrhoea and chlamydia testing did not increase case detection in an HIV clinical cohort 1999–2007. *Sex Transm Infect* 2011;87:469–75.
- 23 Remis RS, Liu J, Loutfy M, *et al*. The epidemiology of sexually transmitted co-infections in HIV-positive and HIV-negative African-Caribbean women in Toronto. *BMC Infect Dis* 2013;13:550.
- 24 Burchell AN, Bayoumi AM, Rourke SB, *et al*. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002–09. *J Antimicrob Chemother* 2012;67:2755–65.
- 25 Hansen L, Barnett J, Wong T, *et al*. STD and HIV counseling practices of British Columbia primary care physicians. *AIDS Patient Care STDs* 2005;19:40–8.
- 26 Government of Canada PHA of C. Important Notice—Public Health Information Update on the Treatment for Gonococcal Infection—Public Health Agency of Canada. 2011 [cited 11 December 2013]. <https://www.phac-aspc.gc.ca/std-mts/sti-its/alert/2011/alert-gono-eng.php>
- 27 Public Health Ontario. *Guidelines for testing and treatment of Gonorrhoea in Ontario*. Toronto, ON: Public Health Ontario, 2013.
- 28 Allen VG, Mitterni L, Seah C, *et al*. *Neisseria gonorrhoeae* treatment failure and susceptibility to cefixime in Toronto, Canada. *JAMA* 2013;309:163–70.